Parkinson's Disease Center and Movement Disorders Clinic

Click on the Expand plus sign sign to list the poster and platform presentations by year. Then click on the link to view that presentation.

2019

Collapse All | Expand All

 

    Movement Disorder Society (MDS)
    23rd International Congress of Parkinson's Disease and Movement Disorders in Nice, France (Sept. 22-26, 2019)
    • Implementation of a peer-to-peer mentoring intervention for center of excellence coordinators.
      [Previously Presented]

      Hunter CB, Arney K, Fleisher JE, Palmentera PR, Shurer J, Cubillos F

    American Academy of Neurology (AAN)
    71st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)
    • Genome-wide association study meta-analysis for Parkinson disease motor subtypes.
      [Platform Presentation]

      Alfradique-Dunham I, Blauwendraat C, Al-Ouran R, von Coelln R, Tan M, Hill EJ, et al.

    • Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study.

      Brashear A, Truong DD, Comella CL, Jankovic J, Patel AT, Prawdzik G, et al.

    • RECLAIM-DCP: A randomized, double-blind, placebo-controlled study of deutetrabenazine for the treatment of dyskinesia in cerebral palsy in children and adolescents.

      Claassen DO, Mink JW, Parnes M, Gordon MF, Barkay H, Wieman M, et al.

    • Capturing Parkinson's disease heterogeneity with quantitative mobility measures.
      [Platform Presentation]

      Hill EJ, Alfradique-Dunham I, Mangleburg CG, Ripperger B, Stillwell A, Rao S, et al.

    • Bradykinesia, mitochondrial myopathy and progressive ophthalmoplegia associated with a novel DNM1L mutation.

      Parnes M, Bashir HH, Jankovic J

    Parkinson's Foundation
    Centers of Excellence Leadership Conference in Chandler, Ariz. (April 3-5, 2019)

2018

Collapse All | Expand All

 

    Huntington Study Group (HSG)
    Annual Meeting in Houston, Texas (Nov. 8-10, 2018)
    Movement Disorder Society (MDS)
    22nd International Congress of Parkinson's Disease and Movement Disorders in Hong Kong, China (Oct. 5-9, 2018)
    • Improvement in patient perceived quality of life with daxibotulinumtoxinA for injection in adults with cervical dystonia.

      Comella C, Brashear A, Jankovic J, Truong D, Patel A, Evatt M, et al.

    • Predictors of alcohol responsiveness in dystonia.

      Junker J, Brandt V, Berman B, Vidailhet M, Roze E, Weissbach A, et al.

    • Consensus for the measurement of the camptocormia angle.

      Margraf N, Wolke R, Granert O, Berardelli A, Berg D, Bloem B, et al.

    • Integrated whole exome sequencing and chromosomal microarray in familial Parkinson's disease.

      Robak L, Du R, Yuan B, Gu S, Akdemir Z, Jankovic J, et al.

    • Accuracy of the International Parkinson Disease and Movement Disorder Society progressive supranuclear palsy diagnostic criteria (IPD-MDS-PSP).

      Shoeibi A, Litvan I, Juncos J, Bordelon Y, Riley D, Reich S, et al.

    • Genome-wide association study identifies common genetic variants associated with cervical dystonia.

      Sun Y, Hui Q, Perlmutter J, Ruehl S, Klein C, Jankovic J, et al.

    • Erotophonophilia and severe impulse control disorder in a patient with Parkinson's disease.

      vander Linden C, Colle H, Colle D, Jankovic J

    American Academy of Neurology (AAN)
    70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)

2017

Collapse All | Expand All

 

    Movement Disorder Society (MDS)
    21st International Congress of Parkinson's Disease and Movement Disorders in Vancouver, BC, Canada (June 4-8, 2017)
    • Whole exome sequencing in essential tremor.

      Alfradique-Dunham I, Robak LA, Kaw A, Fagbongbe OI, Ternes K, Young E, et al.

    • A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia.
      [Previously Presented]

      Comella C, Jankovic J, Truong D, Brashear A, Patel A, Evatt M, et al.

    • Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD probe study.

      Dashtipour K, Mari Z, Jankovic J, Adler C, Schwartz M, Brin M

    • Treatable rare movement disorders.

      Gatto E, Jinnah H, Espay A, Jankovic J, Bhatia K, Rodriguez M, et al.

    • A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome.

      Gilbert D, Murphy T, Jankovic J, Budman C, Black K, Kurlan R, et al.

    • Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease.

      Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, et al.

    • Leg stereotypy disorder: Phenomenology and prevalence.

      Jankovic J, Lotia M, York MK, Strutt AM

    • Emotion regulation and neuropsychological status in psychogenic subtypes.

      Scott B, Strutt A, Lundberg-Love P, Schmitt A, Jankovic J, Bowers D

    • Hemidystonia associated with Alexander disease.

      Vijayakumar D, Lewis RA, Fuller GN, Dhar SU, Machol K, Robak L, et al.

    American Academy of Neurology (AAN)
    69th Annual Meeting in Boston, Mass. (April 22-28, 2017)

<2016

Collapse All | Expand All